Immunovant halts development of its lead drug candidate, imeroprubart, in skin lupus following a trial miss.
Yahoo
Skip to navigation
Skip to main content
Skip to right column
Immunovant Stock Slides After Biotech Scraps Autoimmune Drug Program ·
Barrons.com
·
Dreamstime
